Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and C11-AMT PET in Metastatic Melanoma
NCT03089606Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Apr 2017
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in melanoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Association of Baseline C11-AMT PET SUV Max Value With Objective Response at 12 weeks. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03089606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089606.